Cancer Research and Treatment

Original Articles

Gynecologic cancer

Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers: Joseph J. Noh, Min Kyu Kim, Min Chul Choi, Jeong-Won Lee, Hyun Park, Sang Geun Jung, Won Duk Joo, Seung Hun Song, Chan Lee; Cancer Res Treat. 2022;54(4):1200-1208. Published online December 13, 2021; DOI: https://doi.org/10.4143/crt.2021.828

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was to investigate the frequency of mismatch repair deficiency/high microsatellite instability (MMRd/MSI-H) in gynecologic malignancies and the efficacy of immune checkpoint inhibitors (ICIs) in patients with recurrent gynecologic cancers according to MMR/MSI status.
Materials and Methods
We conducted a multi-center retrospective review on the patients who were diagnosed with gynecologic cancers between 2015 and 2020. Their clinicopathologic information, results of immunohistochemistry staining for MLH1/MSH2/MSH6/PMS2 and MSI analysis, tumor response to treatment with ICIs were investigated.
Results
Among 1,093 patients included in the analysis, MMRd/MSI-H was most frequent in endometrial/uterine cancers (34.8%, 164/471), followed by ovarian, tubal, and peritoneal cancers (12.8%, 54/422) and cervical cancer (11.3%, 21/186). When assessed by histology without regard for cancer types, the frequency of MMRd/MSI-H was 11.0% (38/345) in high-grade serous adenocarcinoma, 38.6% (117/303) in endometrioid adenocarcinoma, and 30.2% (16/53) in carcinosarcoma. A total of 114 patients were treated with ICIs at least once. The objective response rate (ORR) was 21.6% (8/37) in cervical cancer, 4.7% (2/43) in ovarian cancer, and 25.8% (8/31) in endometrial/uterine cancers. Univariate regression analysis identified MMRd/MSI-H as the only significant factor associated with the ORR (28.9% [11/38] vs. 11.8% [9/76]; odds ratio, 3.033; 95% confidence interval, 1.129–8.144; p=0.028).
Conclusion
The frequency of MMRd/MSI-H is moderate to high in gynecologic cancers in the Korean population. MMRd/MSI-H could be effective predictive biomarkers in gynecologic cancers of any type.

Citations

Citations to this article as recorded by

Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis
Youwen Zhu, Kun Liu, Hong Zhu
Journal of Gynecologic Oncology.2025;[Epub] CrossRef
ATP13A2 as a prognostic biomarker and its correlation with immune infiltration in cervical cancer: A retrospective study
Zhi Zhao, Yijie Peng, Yuanyuan Yang, Shuaiyu Li, Jiang Ling, Zhenyu Zhu, Chenfeng He
Journal of Cellular and Molecular Medicine.2025;[Epub] CrossRef
Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report
Juan Lang, Qianqian Liu, Rong Ji, Miao Qiu, Siben Wang, Qingmeng Liu, Dapeng Li, Ping Chen, Zhongkui Xiong
Frontiers in Immunology.2025;[Epub] CrossRef
Frequency of microsatellite instability in gynecologic cancers and the efficacy of immune checkpoint inhibitors treated: real-world data from a single gynecologic center
Wei Kuang, Jing Zeng, Lingling Tong, Qianqi Liu, Huanxin Sun, Min Feng, Dongni Liang, Wei Wang, Cheng Wang
Frontiers in Immunology.2025;[Epub] CrossRef
The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?
Fadila Kouhen, Adil El Ghanmi, Hanane Inghaoun, Hayat Miftah, Bouchra Ghazi, Abdallah Badou
Frontiers in Immunology.2025;[Epub] CrossRef
Cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases
Yu Miyama, Tomomi Kato, Masayasu Sato, Akira Yabuno, Kosei Hasegawa, Masanori Yasuda
Diagnostic Pathology.2024;[Epub] CrossRef
Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST
Shanhui Liang, Huijuan Ge, Shuling Zhou, Jie Tang, Yanzi Gu, Xiaohua Wu, Jin Li
Gynecologic Oncology.2024; 187: 64. CrossRef
Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer
Renata Pacholczak-Madej, Michele Bartoletti, Lucia Musacchio, Mirosława Püsküllüoglu, Paweł Blecharz, Domenica Lorusso
Expert Review of Anticancer Therapy.2024; 24(8): 717. CrossRef
Expression patterns of mismatch repair proteins in cervical cancer uncover independent prognostic value of MSH-2
Madeleine Charlotte van den Berg, Hege F Berg, Tomasz Stokowy, Erling A Hoivik, Kathrine Woie, Hilde Engerud, Akinyemi I Ojesina, Ingfrid Salvesen Haldorsen, Jone Trovik, Bjørn I Bertelsen, Camilla Krakstad, Mari Kyllesø Halle
International Journal of Gynecological Cancer.2024; 34(7): 993. CrossRef
Cervical cancer: a new era
Giuseppe Caruso, Matthew K Wagar, Heng-Cheng Hsu, Jorge Hoegl, Guido Martin Rey Valzacchi, Andreina Fernandes, Giuseppe Cucinella, Seda Sahin Aker, Aarthi S Jayraj, Jessica Mauro, Rene Pareja, Pedro T Ramirez
International Journal of Gynecological Cancer.2024; 34(12): 1946. CrossRef
Unraveling the Heterogeneity of Deficiency of Mismatch Repair Proteins in Endometrial Cancer: Predictive Biomarkers and Assessment Challenges
Filomena M. Carvalho, Jesus P. Carvalho
Cancers.2024; 16(20): 3452. CrossRef
Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review
Na Li, Zixuan Wan, Dongyan Lu, Ruilian Chen, Xiaowei Ye
Frontiers in Immunology.2023;[Epub] CrossRef
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Guillaume Mestrallet, Matthew Brown, Cansu Cimen Bozkus, Nina Bhardwaj
Frontiers in Immunology.2023;[Epub] CrossRef
Heterogeneous expression of mismatch repair proteins and interpretation of immunohistochemical results in colorectal cancer and endometrial cancer
Xiangzhao Li, Shifen Zhang, Jiamin Zeng, Sha-sha Song, Xiaoqing Liu, Wei Kang, Minyi Liang, Rui Yang, Hong Li, Li Liang
Pathology - Research and Practice.2023; 248: 154647. CrossRef
Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies
Migang Kim, Chi-Son Chang, Min Chul Choi, Jeong-Won Lee, Hyun Park, Won Duk Joo
Yonsei Medical Journal.2023; 64(10): 587. CrossRef
Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
Linlin Liu, Xianbo Deng, Shuang Guo, Shouhua Yang
Diagnostic Pathology.2023;[Epub] CrossRef
Adverse Effect of the Duration of Antibiotic Use Prior to Immune Checkpoint Inhibitors on the Overall Survival of Patients with Recurrent Gynecologic Malignancies
Hye-Ji Jung, Jong-Ho Park, Jina Oh, Sae-Mi Lee, Il-Yeo Jang, Jung-Yong Hong, Yoo-Young Lee, Hyun Jin Choi
Cancers.2023; 15(24): 5745. CrossRef
Uterine carcinosarcoma with microsatellite instability - does immunotherapy modify the therapeutic scenario? A case report and literature review
Diocesio Alves Pinto Andrade, Eduardo Paulino, Isabela Panzeri Carlotti Buzatto, Danilo Tadao Wada, Warne Pedro Andrade, Andreia Cristina Melo, Angelica Nogueira-Rodrigues
Brazilian Journal of Oncology.2023;[Epub] CrossRef
Immune checkpoint inhibitors in cervical cancer: Current status and research progress
Yunkai Xie, Weimin Kong, Xiaoling Zhao, He Zhang, Dan Luo, Shuning Chen
Frontiers in Oncology.2022;[Epub] CrossRef

7,761 View
304 Download
22 Web of Science
19 Crossref

Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival: Kyoung Won Noh, Bomi Kim, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Won Kyung Cho, Won Park, Yoo-Young Lee; Cancer Res Treat. 2022;54(1):245-252. Published online April 15, 2021; DOI: https://doi.org/10.4143/crt.2021.023

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the effect of waiting time, from diagnosis to initiation of definitive concurrent chemoradiation (CCRT), on overall survival in cervical cancer patients.
Materials and Methods
Patients with cervical cancer who were treated with definitive CCRT between 2000 and 2017 were retrospectively reviewed. Time from initial pathological diagnosis to definitive CCRT was analyzed both as a continuous variable (per day) and as a categorical variable in two groups (group 1 ≤ median, group 2 > median). Patients with a waiting time of more than 60 days were excluded.
Results
The median waiting time was 14 days (0-60). There were differences between group 1 and group 2 in age and chemotherapy regimens. However, no significant difference was found in the International Federation of Gynecology and Obstetrics stage, cell type, or the number of cycles of chemotherapy received during CCRT. A longer waiting time was associated with poorer overall survival on the Kaplan-Meier curve (group 1 vs. group 2, p=0.042). On multivariate analysis, intervals as either a continuous variable (hazard ratio [HR], 1.023; 95% confidence interval [CI], 1.006 to 1.040; p=0.007) or a categorical variable (HR, 1.513; 95% CI, 1.073 to 2.134; p=0.018), FIGO stage, cell type, and the number of cycles of chemotherapy received during CCRT were significant independent prognostic factors for overall survival.
Conclusion
A shorter waiting time from pathological diagnosis to definitive CCRT showed benefit on overall survival. Our findings suggest that an effort to minimize waiting times should be recommended in cervical cancer patients who are candidates for CCRT.

Citations

Citations to this article as recorded by

Effect of waiting time for radiotherapy after last induction chemotherapy on prognosis of locally advanced nasopharyngeal carcinoma
Kui‐Xuan Zhu, Ting Ding, Yi‐Min E, Hong‐Wei Yang, Rui‐Ping Wu, Run‐Jia Liu, Ling‐Li Zhou, Wen‐Jie Fu, Mei‐Ping Jiang, Xiao‐Li Wang
Head & Neck.2024; 46(5): 1189. CrossRef
An Innovative Thermal Imaging Prototype for Precise Breast Cancer Detection: Integrating Compression Techniques and Classification Methods
Khaled S. Ahmed, Fayroz F. Sherif, Mohamed S. Abdallah, Young-Im Cho, Shereen M. ElMetwally
Bioengineering.2024; 11(8): 764. CrossRef
Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study
Amy P. Hack, Ronald P. Zweemer, Trudy N. Jonges, Femke van der Leij, Cornelis G. Gerestein, Max Peters, Ina M. Jürgenliemk-Schulz, Peter S.N. van Rossum
Gynecologic Oncology.2022; 165(2): 339. CrossRef
The Role of Conization before Radical Hysterectomy in Cervical Cancer including High Risk Factors of Recurrence: Propensity Score Matching
Chi-Son Chang, Ji Song Min, Ki Hyeon Song, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Yoo-Young Lee
Cancers.2022; 14(16): 3863. CrossRef
Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study
Yu Min, Zheran Liu, Rendong Huang, Ruidan Li, Jing Jin, Zhigong Wei, Ling He, Yiyan Pei, Ning Li, Yongllin Su, Xiaolin Hu, Xingchen Peng
Journal of Translational Medicine.2022;[Epub] CrossRef

7,374 View
198 Download
7 Web of Science
5 Crossref

Gynecologic Cancer

Early Metabolic Response Assessed Using ¹⁸F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer: Nalee Kim, Won Park, Won Kyung Cho, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee, Tae-Joong Kim, Chel Hun Choi, Yoo-Young Lee, Young Seok Cho; Cancer Res Treat. 2021;53(3):803-812. Published online December 9, 2020; DOI: https://doi.org/10.4143/crt.2020.1251

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to identify the prognostic value of early metabolic response assessed using ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) during radiation therapy (RT) for cervical cancer.
Materials and Methods
We identified 116 patients treated with definitive RT, including FDG-PET/CT–guided intracavitary brachytherapy, between 2009 and 2018. We calculated parameters including maximum (SUV_max) and mean standardized uptake values (SUV_mean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for baseline FDG-PET/CT (PET_base) and image-guided brachytherapy planning FDG-PET/CT (PET_IGBT). Multivariable analyses of disease-free survival (DFS) and overall survival (OS) were performed.
Results
We observed a time-dependent decrease in PET parameters between PET_base and PET_IGBT; ΔSUV_max, ΔSUV_mean, ΔMTV, and ΔTLG were 65%, 61%, 78%, and 93%, respectively. With a median follow-up of 59.5 months, the 5-year DFS and OS rates were 66% and 79%, respectively. Multivariable analysis demonstrated that ΔSUV_max ≥ 50% was associated with favorable DFS (hazard ratio [HR], 2.56; 95% confidence interval [CI], 1.14 to 5.77) and OS (HR, 5.14; 95% CI, 1.55 to 17.01). Patients with ΔSUV_max ≥ 50% (n=87) showed better DFS and OS than those with ΔSUV_max < 50% (n=29) (DFS, 76% vs. 35%, p < 0.001; OS, 90% vs. 41%, p < 0.001, respectively). Adenocarcinoma was frequently observed in ΔSUV_max < 50% compared to ΔSUV_max ≥ 50% (27.6% vs. 10.3%, p=0.003). In addition, models incorporating metabolic parameters showed improved accuracy for predicting DFS (p=0.012) and OS (p=0.004) than models with clinicopathologic factors.
Conclusion
Changes in metabolic parameters, especially those in SUV_max by > 50%, can help improve survival outcome predictions for patients with cervical cancer treated with definitive RT.

Citations

Citations to this article as recorded by

Personalized strategies for brachytherapy of cervix cancer
Guillaume Camprodon, Alexandra Gabro, Zineb El Ayachi, Supriya Chopra, Remi Nout, Philippe Maingon, Cyrus Chargari
Cancer/Radiothérapie.2024; 28(6-7): 610. CrossRef
Brachytherapy for cervical cancer: from intracavitary to interstitial technique
Xiaojing Yang, Hanru Ren, Zhen Li, Jie Fu
Frontiers in Oncology.2024;[Epub] CrossRef
Application of three-dimensional multi-imaging combination in brachytherapy of cervical cancer
Zhaoming Zhang, Ning Zhang, Guanghui Cheng
La radiologia medica.2023; 128(5): 588. CrossRef
MRI- and PET-Based Assessment of Radiological and Clinical Factors Associated With Cervical Cancer Response to External Beam Radiation Therapy
Arun G Paul, Steven Miller, Lance K Heilbrun, Daryn W Smith
Cureus.2022;[Epub] CrossRef

6,361 View
175 Download
5 Web of Science
4 Crossref

Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer: E Sun Paik, Hyun Jin Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Chel Hun Choi; Cancer Res Treat. 2018;50(2):461-473. Published online May 22, 2017; DOI: https://doi.org/10.4143/crt.2017.104

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to develop molecular classifier that can predict lymphatic invasion and their clinical significance in epithelial ovarian cancer (EOC) patients.
Materials and Methods
We analyzed gene expression (mRNA, methylated DNA) in data from The Cancer Genome Atlas. To identify molecular signatures for lymphatic invasion, we found differentially expressed genes. The performance of classifier was validated by receiver operating characteristics analysis, logistic regression, linear discriminant analysis (LDA), and support vector machine (SVM). We assessed prognostic role of classifier using random survival forest (RSF) model and pathway deregulation score (PDS). For external validation,we analyzed microarray data from 26 EOC samples of Samsung Medical Center and curatedOvarianData database.
Results
We identified 21 mRNAs, and seven methylated DNAs from primary EOC tissues that predicted lymphatic invasion and created prognostic models. The classifier predicted lymphatic invasion well, which was validated by logistic regression, LDA, and SVM algorithm (C-index of 0.90, 0.71, and 0.74 for mRNA and C-index of 0.64, 0.68, and 0.69 for DNA methylation). Using RSF model, incorporating molecular data with clinical variables improved prediction of progression-free survival compared with using only clinical variables (p < 0.001 and p=0.008). Similarly, PDS enabled us to classify patients into high-risk and low-risk group, which resulted in survival difference in mRNA profiles (log-rank p-value=0.011). In external validation, gene signature was well correlated with prediction of lymphatic invasion and patients’ survival.
Conclusion
Molecular signature model predicting lymphatic invasion was well performed and also associated with survival of EOC patients.

Citations

Citations to this article as recorded by

Identifying Stage II Colorectal Cancer Recurrence Associated Genes by Microarray Meta-Analysis and Building Predictive Models with Machine Learning Algorithms
Wei Lu, Xiang Pan, Siqi Dai, Dongliang Fu, Maxwell Hwang, Yingshuang Zhu, Lina Zhang, Jingsun Wei, Xiangxing Kong, Jun Li, Qian Xiao, Kefeng Ding, Quan Cheng
Journal of Oncology.2021; 2021: 1. CrossRef

10,415 View
249 Download
5 Web of Science
1 Crossref

Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies: Eun Jin Heo, Young Jae Cho, William Chi Cho, Ji Eun Hong, Hye-Kyung Jeon, Doo-Yi Oh, Yoon-La Choi, Sang Yong Song, Jung-Joo Choi, Duk-Soo Bae, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Woong-Yang Park, Byoung-Gie Kim, Jeong-Won Lee; Cancer Res Treat. 2017;49(4):915-926. Published online January 4, 2017; DOI: https://doi.org/10.4143/crt.2016.322

Abstract PDF Supplementary Material PubReader ePub

Purpose
Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research.
Materials and Methods
We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues.
Results
Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023).
Conclusion
PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.

Citations

Citations to this article as recorded by

Patient-derived xenograft models: Current status, challenges, and innovations in cancer research
Minqi Liu, Xiaoping Yang
Genes & Diseases.2025; 12(5): 101520. CrossRef
Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts
Joseph J. Caumanns, Shang Li, Gert J. Meersma, Evelien W. Duiker, Ate G. J. van der Zee, G. Bea A. Wisman, Steven de Jong
Scientific Reports.2025;[Epub] CrossRef
The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression
Yoo-Young Lee, Ji-Yoon Ryu, Young-Jae Cho, Ju-Yeon Choi, Jung-Joo Choi, Chel Hun Choi, Jason K. Sa, Jae Ryoung Hwang, Jeong-Won Lee
Cancer Cell International.2024;[Epub] CrossRef
Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience
Ruri Nishie, Tomohito Tanaka, Kensuke Hirosuna, Shunsuke Miyamoto, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Shoko Ueda, Natsuko Morita, Sousuke Hashida, Atsushi Daimon, Shinichi Terada, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Tan
Journal of Clinical Medicine.2024; 13(9): 2718. CrossRef
Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer
Byumseok Koh, Ji-Yoon Ryu, Joseph J. Noh, Jae Ryoung Hwang, Jung-Joo Choi, Young-Jae Cho, Jiyoon Jang, Jeong Hyeon Jo, Kwangho Lee, Jeong-Won Lee
Gynecologic Oncology.2024; 188: 60. CrossRef
Recent advances in lung cancer organoid (tumoroid) research (Review)
Qiang Zhang, Mingyang Zhang
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Patient‐derived xenograft model in colorectal cancer basic and translational research
Xiaofeng Liu, Zechang Xin, Kun Wang
Animal Models and Experimental Medicine.2023; 6(1): 26. CrossRef
Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment
Kenneth K. W. To, Ka M. Cheung, William C. S. Cho
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7217. CrossRef
Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer
Chi-Son Chang, Ji-Yoon Ryu, June-Kuk Choi, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Joseph J. Noh, Chan Mi Lee, Ji Eun Won, Hee Dong Han, Jeong-Won Lee
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review
Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, Luiz Fernando Lopes
Cancers.2023; 15(11): 2990. CrossRef
Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice
Mingtang Zeng, Zijing Ruan, Jiaxi Tang, Maozhu Liu, Chengji Hu, Ping Fan, Xinhua Dai
Cancer Cell International.2023;[Epub] CrossRef
Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Prostate Cancer
佳慧吴
Advances in Clinical Medicine.2023; 13(06): 10496. CrossRef
Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma
Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Ju-Yeon Choi, Jung-Joo Choi, Jason K. Sa, Hyun-Soo Kim, Jeong-Won Lee
Biomedicine & Pharmacotherapy.2023; 168: 115792. CrossRef
Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model
Yukari Oda, Kaoru Niimi, Kosuke Yoshida, Satoshi Tamauchi, Akira Yokoi, Yuko Yasui, Yuki Nishiko, Mayu Shibata, Yusuke Shimizu, Masato Yoshihara, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Eiko Yamamoto, Hiroaki Kajiyama
BMC Cancer.2023;[Epub] CrossRef
Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models
Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho, Jae-Hoon Kim
Cancers.2022; 14(3): 829. CrossRef
Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine
Christine Yee, Kristie-Ann Dickson, Mohammed N. Muntasir, Yue Ma, Deborah J. Marsh
Frontiers in Bioengineering and Biotechnology.2022;[Epub] CrossRef
Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer
Jung-In Shim, Ji-Yoon Ryu, Soo Young Jeong, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jason K. Sa, Jeong-Won Lee
Gynecologic Oncology.2022; 165(2): 270. CrossRef
Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review
Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
Journal of Clinical Medicine.2022; 11(9): 2606. CrossRef
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
Alessandra Ciucci, Marianna Buttarelli, Anna Fagotti, Giovanni Scambia, Daniela Gallo
Cellular and Molecular Life Sciences.2022;[Epub] CrossRef
Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee
Clinical Cancer Research.2022; 28(17): 3850. CrossRef
Harnessing preclinical models for the interrogation of ovarian cancer
Tianyu Qin, Junpeng Fan, Funian Lu, Li Zhang, Chen Liu, Qiyue Xiong, Yang Zhao, Gang Chen, Chaoyang Sun
Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
The Development of a Three-Dimensional Platform for Patient-Derived Ovarian Cancer Tissue Models: A Systematic Literature Review
Lusine Sevinyan, Priyanka Gupta, Eirini Velliou, Thumuluru Kavitha Madhuri
Cancers.2022; 14(22): 5628. CrossRef
A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report
Yunke Huang, Jing Xu, Ke Li, Jing Wang, Yilin Dai, Yu Kang
Cancer Management and Research.2021; Volume 13: 2849. CrossRef
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer
Soo Young Jeong, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae-Ryoung Hwang, Binnari Kim, Yoo-Young Lee, Hyun-Soo Kim, Jeong-Won Lee
Gynecologic Oncology.2021; 162(1): 173. CrossRef
Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies
Paula Cunnea, Christina Fotopoulou, Jennifer Ploski, Fabian Trillsch, Sven Mahner, Mirjana Kessler
Cancers.2021; 13(13): 3349. CrossRef
Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
International Journal of Molecular Sciences.2021; 22(17): 9369. CrossRef
Methodological aspects of creation of patient-derived tumor xenografts
A S Goncharova, A N Shevchenko, I R Dashkova, A E Anisimov
Kazan medical journal.2021; 102(5): 694. CrossRef
The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis
Jinseong Kim, Man Kyu Shim, Young-Jae Cho, Sangmin Jeon, Yujeong Moon, Jiwoong Choi, Jeongrae Kim, Jaewan Lee, Jeong-Won Lee, Kwangmeyung Kim
Biomaterials.2021; 279: 121189. CrossRef
Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials
Ana Karen Mendoza-Martinez, Daniela Loessner, Alvaro Mata, Helena S. Azevedo
Cancers.2021; 13(22): 5745. CrossRef
Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research
Magdalena Cybula, Lin Wang, Luyao Wang, Ana Luiza Drumond-Bock, Katherine M. Moxley, Doris M. Benbrook, Camille Gunderson-Jackson, Maria J. Ruiz-Echevarria, Resham Bhattacharya, Priyabrata Mukherjee, Magdalena Bieniasz
Cancers.2021; 13(24): 6288. CrossRef
Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects
Sharmin Seraj, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn
Biochemical Pharmacology.2020; 171: 113735. CrossRef
The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance
Jiahao Shi, Yongyun Li, Renbing Jia, Xianqun Fan
International Journal of Cancer.2020; 146(8): 2078. CrossRef
KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer
Jinju Lee, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn
Journal of Controlled Release.2020; 321: 184. CrossRef
A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma
Tomoki Yamano, Shuji Kubo, Naohiro Tomita
Cancer Medicine.2020; 9(10): 3337. CrossRef
Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
E Sun Paik, Tae-Hyun Kim, Young Jae Cho, Jiyoon Ryu, Jung-Joo Choi, Yoo-Young Lee, Tae-Joong Kim, Chel-Hun Choi, Woo Young Kim, Jason K. Sa, Jin-Ku Lee, Byoung-Gie Kim, Duk-Soo Bae, Hee Dong Han, Hyung Jun Ahn, Jeong-Won Lee
Scientific Reports.2020;[Epub] CrossRef
A Biobank of Colorectal Cancer Patient-Derived Xenografts
Suad M. Abdirahman, Michael Christie, Adele Preaudet, Marie C. U. Burstroem, Dmitri Mouradov, Belinda Lee, Oliver M. Sieber, Tracy L. Putoczki
Cancers.2020; 12(9): 2340. CrossRef
Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis
Evgeny Chirshev, Nozomi Hojo, Antonella Bertucci, Linda Sanderman, Anthony Nguyen, Hanmin Wang, Tise Suzuki, Emmanuel Brito, Shannalee R. Martinez, Christine Castañón, Saied Mirshahidi, Marcelo E. Vazquez, Pamela Wat, Kerby C. Oberg, Yevgeniya J. Ioffe, J
Molecular Oncology.2020; 14(11): 2796. CrossRef
Human-Derived Model Systems in Gynecological Cancer Research
Kadi Lõhmussaar, Matteo Boretto, Hans Clevers
Trends in Cancer.2020; 6(12): 1031. CrossRef
Spontaneous and Induced Animal Models for Cancer Research
Anca Onaciu, Raluca Munteanu, Vlad Cristian Munteanu, Diana Gulei, Lajos Raduly, Richard-Ionut Feder, Radu Pirlog, Atanas G. Atanasov, Schuyler S. Korban, Alexandru Irimie, Ioana Berindan-Neagoe
Diagnostics.2020; 10(9): 660. CrossRef
Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer
Joseph J. Noh, Myeong-Seon Kim, Young-Jae Cho, Soo-Young Jeong, Yoo-Young Lee, Ji-Yoon Ryu, Jung-Joo Choi, Illju Bae, Zhaoyan Wu, Byoung-Gie Kim, Jae Ryoung Hwang, Jeong-Won Lee
Pharmaceutics.2020; 12(10): 987. CrossRef
Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures
Sofia Abreu, Fernanda Silva, Rita Mendes, Teresa F. Mendes, Marta Teixeira, Vítor E. Santo, Erwin R. Boghaert, Ana Félix, Catarina Brito
Scientific Reports.2020;[Epub] CrossRef
Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer
Jae Ryoung Hwang, Woo Young Kim, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Myeong-Sun Kim, Ji Hye Kim, E. Sun Paik, Yoo-Young Lee, Hee-Dong Han, Jeong-Won Lee
Cell Death & Disease.2020;[Epub] CrossRef
Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma
Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim
Translational Oncology.2019; 12(2): 269. CrossRef
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Giovanna Damia, Massimo Broggini
Cancers.2019; 11(1): 119. CrossRef
Establishment of patient‐derived xenograft model in ovarian cancer and its influence factors analysis
Jianfa Wu, Yunxi Zheng, Qi Tian, Ming Yao, Xiaofang Yi
Journal of Obstetrics and Gynaecology Research.2019; 45(10): 2062. CrossRef
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
Seiji Okada, Kulthida Vaeteewoottacharn, Ryusho Kariya
Cells.2019; 8(8): 889. CrossRef
Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research
Akira Inoue, Angela K. Deem, Scott Kopetz, Timothy P. Heffernan, Giulio F. Draetta, Alessandro Carugo
Cancers.2019; 11(9): 1321. CrossRef
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers
Jason K. Sa, Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Jihye Kim, Myeong Seon Kim, E. Sun Paik, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Yeri Lee, Nam-Gu Her, Yong Jae Shin, Hee Jin Cho,
Genome Biology.2019;[Epub] CrossRef
The latest animal models of ovarian cancer for novel drug discovery
Elizabeth Magnotti, Wayne A. Marasco
Expert Opinion on Drug Discovery.2018; 13(3): 249. CrossRef
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli, Elvira Pelosi
Medicines.2018; 5(1): 16. CrossRef
NIRF Optical/PET Dual-Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye
Caiqin Zhang, Yong Zhao, Ningning Zhao, Dengxu Tan, He Zhang, Xue Chen, Hai Zhang, Jiaze An, Changhong Shi, Mengbin Li
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef
Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models
Kyung Jin Eoh, Young Shin Chung, So Hyun Lee, Sun-Ae Park, Hee Jung Kim, Wookyeom Yang, In Ok Lee, Jung-Yun Lee, Hanbyoul Cho, Doo Byung Chay, Sunghoon Kim, Sang Wun Kim, Jae-Hoon Kim, Young Tae Kim, Eun Ji Nam
Cancer Research and Treatment.2018; 50(3): 956. CrossRef
CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer
Yeongseon Byeon, Jeong-Won Lee, Whan Soo Choi, Ji Eun Won, Ga Hee Kim, Min Gi Kim, Tae In Wi, Jae Myeong Lee, Tae Heung Kang, In Duk Jung, Young-Jae Cho, Hyung Jun Ahn, Byung Cheol Shin, Young Joo Lee, Anil K. Sood, Hee Dong Han, Yeong-Min Park
Cancer Research.2018; 78(21): 6247. CrossRef

21,801 View
739 Download
57 Web of Science
53 Crossref

Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer: E Sun Paik, Insuk Sohn, Sun-Young Baek, Minhee Shim, Hyun Jin Choi, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Yoo-Young Lee, Duk-Soo Bae; Cancer Res Treat. 2017;49(3):635-642. Published online September 27, 2016; DOI: https://doi.org/10.4143/crt.2016.282

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to evaluate the prognostic significance of pre-treatment complete blood cell count (CBC), including white blood cell (WBC) differential, in epithelial ovarian cancer (EOC) patients with primary debulking surgery (PDS) and to develop nomograms for platinum sensitivity, progression-free survival (PFS), and overall survival (OS).
Materials and Methods
We retrospectively reviewed the records of 757 patients with EOC whose primary treatment consisted of surgical debulking and chemotherapy at Samsung Medical Center from 2002 to 2012. We subsequently created nomograms for platinum sensitivity, 3-year PFS, and 5-year OS as prediction models for prognostic variables including age, stage, grade, cancer antigen 125 level, residual disease after PDS, and pre-treatment WBC differential counts. The models were then validated by 10-fold cross-validation (CV).
Results
In addition to stage and residual disease after PDS, which are known predictors, lymphocyte and monocyte count were found to be significant prognostic factors for platinum-sensitivity, platelet count for PFS, and neutrophil count for OS on multivariate analysis. The area under the curves of platinum sensitivity, 3-year PFS, and 5-year OS calculated by the 10-fold CV procedure were 0.7405, 0.8159, and 0.815, respectively.
Conclusion
Prognostic factors including pre-treatment CBC were used to develop nomograms for platinum sensitivity, 3-year PFS, and 5-year OS of patients with EOC. These nomograms can be used to better estimate individual outcomes.

Citations

Citations to this article as recorded by

The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer
Xianglin Nie, Ting Xu, Lin Zhang, Wenjun Cheng
European Journal of Obstetrics & Gynecology and Reproductive Biology.2024; 294: 97. CrossRef
Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis
Qingyi Wang, Zhuo Chang, Xiaofang Liu, Yunrui Wang, Chuwen Feng, Yunlu Ping, Xiaoling Feng
Journal of Medical Internet Research.2024; 26: e48527. CrossRef
Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics
Maowei Ni, Danying Wan, Junzhou Wu, Wangang Gong, Junjian Wang, Zhiguo Zheng
Journal of Proteomics.2024; 304: 105234. CrossRef
Preoperative Immune Cell Dysregulation Accompanies Ovarian Cancer Patients into the Postoperative Period
Jonas Ulevicius, Aldona Jasukaitiene, Arenida Bartkeviciene, Zilvinas Dambrauskas, Antanas Gulbinas, Daiva Urboniene, Saulius Paskauskas
International Journal of Molecular Sciences.2024; 25(13): 7087. CrossRef
A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma
Fengfeng Li, Dongyuan Wang, Nana Wang, Linlin Wu, Bo Yu
Scientific Reports.2024;[Epub] CrossRef
Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data
Li-Rong Yang, Mei Yang, Liu-Lin Chen, Yong-Lin Shen, Yuan He, Zong-Ting Meng, Wan-Qi Wang, Feng Li, Zhi-Jin Liu, Lin-Hui Li, Yu-Feng Wang, Xin-Lei Luo
Frontiers in Oncology.2024;[Epub] CrossRef
Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016‐A3) of the treatment strength and prognostic outcomes of conventional or dose‐dense chemotherapy
Yoshio Itani, Hitomi Sakai, Tetsutaro Hamano, Mikiko Asai‐Sato, Masayuki Futagami, Masaki Fujimura, Yoichi Aoki, Nao Suzuki, Yoshio Yoshida, Takayuki Enomoto
Journal of Obstetrics and Gynaecology Research.2023; 49(5): 1400. CrossRef
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
Stanislas Quesada, Michel Fabbro, Jérôme Solassol
Cancers.2022; 14(4): 1098. CrossRef
Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
Cancers.2021; 13(8): 1875. CrossRef
Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
Kazuho Nakanishi, Takashi Yamada, Gen Ishikawa, Shunji Suzuki
Frontiers in Oncology.2021;[Epub] CrossRef
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study
Alberto Farolfi, Emanuela Scarpi, Filippo Greco, Alice Bergamini, Lucia Longo, Sandro Pignata, Claudia Casanova, Gennaro Cormio, Alessandra Bologna, Michele Orditura, Laura Zavallone, Laura Attademo, Valentina Gallà, Elisena Franzese, Eva Pigozzi, Vera Lo
Scientific Reports.2020;[Epub] CrossRef
Pertinence des marqueurs tumoraux, scores (cliniques et biologiques) et algorithmes à visée diagnostique et pronostique devant une masse ovarienne suspecte d’un cancer épithélial. Article rédigé sur la base de la recommandation nationale de bonnes pratiqu
S. Bendifallah, G. Body, E. Daraï, L. Ouldamer
Gynécologie Obstétrique Fertilité & Sénologie .2019; 47(2): 134. CrossRef
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
Cancer Research and Treatment.2019; 51(3): 1144. CrossRef

11,891 View
283 Download
14 Web of Science
13 Crossref

Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer: Taejong Song, Hye-Kyung Jeon, Ji Eun Hong, Jung-Joo Choi, Tae-Joong Kim, Chel Hun Choi, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee; Cancer Res Treat. 2017;49(3):595-606. Published online September 27, 2016; DOI: https://doi.org/10.4143/crt.2016.034

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to investigate whether a proton pump inhibitor (PPI) could enhance chemosensitivity via the inhibition of vacuolar-type H+ ATPase (V-ATPase) in cervical cancer.
Materials and Methods
The expression of V-ATPase was evaluated in 351 formalin-fixed, paraffin-embedded human cervical cancer tissues using immunohistochemistry and compared with clinicopathologic risk factors for disease prognosis. The influence of cell proliferation and apoptosis following V-ATPase siRNA transfection or esomeprazole pretreatment was assessed in cervical cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and enzyme-linked immunosorbent assay, respectively.
Results
Immunohistochemical analysis revealed that V-ATPase was expressed in about 60% of cervical cancer tissue samples (211/351), and the expression was predominantly found in adenocarcinoma histology (p=0.016). Among patients with initially bulky cervical cancer (n=89), those with V-ATPase expression had shorter disease-free survival (p=0.005) and overall survival (p=0.023). Co-treatment with V-ATPase siRNA or esomeprazole with paclitaxel significantly decreased the cell proliferation of cervical cancer cell lines, including HeLa and INT407, compared to cell lines treated with paclitaxel alone (p < 0.01). Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p < 0.05).
Conclusion
V-ATPase was predominantly expressed in cervical adenocarcinoma, and the expression of V-ATPases was associated with poor prognosis. The inhibition of V-ATPase via siRNA or PPI (esomeprazole) might enhance the chemosensitivity of paclitaxel in cervical cancer cells.

Citations

Citations to this article as recorded by

Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women’s Health Initiative
Tarah J. Ballinger, Zora Djuric, Sagar Sardesai, Kathleen M. Hovey, Chris A. Andrews, Theodore M. Brasky, Jian Ting Zhang, Thomas E Rohan, Nazmus Saquib, Aladdin H. Shadyab, Michael Simon, Jean Wactawski-Wende, Robert Wallace, Ikuko Kato
Nutrition and Cancer.2023; 75(1): 265. CrossRef
Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
Jingya Duan, Zisen Zhang, Jinfeng Du, Jihua Zhang, Minmin Li, Canyu Li
OncoTargets and Therapy.2023; Volume 16: 425. CrossRef
Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
Liang Tian, Chongfei Huang, Wenkang Fu, Long Gao, Ningning Mi, Mingzhen Bai, Haidong Ma, Chao Zhang, Yawen Lu, Jinyu Zhao, Xianzhuo Zhang, Ningzu Jiang, Yanyan Lin, Ping Yue, Jinqiu Yuan, Wenbo Meng
Frontiers in Pharmacology.2023;[Epub] CrossRef
Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data
Tigran Makunts, Haroutyun Joulfayan, Kenneth Ta, Ruben Abagyan
Pharmacoepidemiology.2023; 2(3): 272. CrossRef
Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals
Nhi Thi Hong Nguyen, Chih-Wei Huang, Ching-Huan Wang, Ming-Chin Lin, Jason C. Hsu, Min-Huei Hsu, Usman Iqbal, Phung-Anh Nguyen, Hsuan-Chia Yang
Cancers.2022; 14(24): 6083. CrossRef
Emerging insights on the role of V‐ATPase in human diseases: Therapeutic challenges and opportunities
Cátia Santos‐Pereira, Lígia R. Rodrigues, Manuela Côrte‐Real
Medicinal Research Reviews.2021; 41(4): 1927. CrossRef
Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation
Shuitu Feng, Guoqin Qiu, Lihong Yang, Lihua Feng, Xin Fan, Fang Ren, Kaida Huang, Yide Chen
Bioscience Reports.2021;[Epub] CrossRef
Precise Cancer Anti-acid Therapy Monitoring Using pH-Sensitive MnO2@BSA Nanoparticles by Magnetic Resonance Imaging
Rong A, Yuzhu Yao, Xiaolu Guo, Weiqi Jiang, Meng Jiang, Jie Yang, Yingbo Li, Olagbaju Oluwatosin Atinuke, Xuesong Hu, Yuanyuan Li, Xiance Wang, Lili Yang, Xiangliang Yang, Kai Wang, Jun Hu, Xilin Sun
ACS Applied Materials & Interfaces.2021; 13(16): 18604. CrossRef
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition
Deepak Babu, Anwita Mudiraj, Neera Yadav, Chandrashekhar Y.B.V.K., Manas Panigrahi, Phanithi Prakash Babu
Cellular Oncology.2021; 44(4): 889. CrossRef
How can proton pump inhibitors damage central and peripheral nervous systems?
Tigran Makunts, Ruben Abagyan
Neural Regeneration Research.2020; 15(11): 2041. CrossRef
Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance
Shekoufeh Almasi, Yassine El Hiani
Cancers.2020; 12(6): 1624. CrossRef
Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells
Valentina Ranzuglia, Ilaria Lorenzon, Ilenia Pellarin, Maura Sonego, Alessandra Dall’Acqua, Sara D’Andrea, Sara Lovisa, Ilenia Segatto, Michela Coan, Jerry Polesel, Diego Serraino, Patrizia Sabatelli, Paola Spessotto, Barbara Belletti, Gustavo Baldassarre
Oncogene.2020; 39(40): 6370. CrossRef
Elevated expression of the V‐ATPase D2 subunit triggers increased energy metabolite levels in KrasG12D‐driven cancer cells
Jigang Yang, Feihu Guo, Leilei Yuan, Guangxin Lv, Jianhua Gong, Jing Chen
Journal of Cellular Biochemistry.2019; 120(7): 11690. CrossRef
Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2‐acetamidofluorene
Marwa Matboli, Asmaa Abd ElGwad, Amany H. Hasanin, Ahmed El‐Tawdi, Eman K. Habib, Rasha Ahmed` Elmansy, Doaa Ibrahim, Hanan Shehata, Fathy Tash
Journal of Cellular Biochemistry.2019; 120(9): 14946. CrossRef
Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer
Bradleigh Whitton, Haruko Okamoto, Graham Packham, Simon J. Crabb
Cancer Medicine.2018; 7(8): 3800. CrossRef
Protein Pump Inhibitors Esomeprazole and Pantoprazole Increase the Chemosensitivity of CML cells against Imatinib
Merve Ergül, Mustafa Ergül
Cumhuriyet Medical Journal.2018;[Epub] CrossRef
Value of pH regulators in the diagnosis, prognosis and treatment of cancer
Sara Granja, Diana Tavares-Valente, Odília Queirós, Fátima Baltazar
Seminars in Cancer Biology.2017; 43: 17. CrossRef
Triple-edged therapy targeting intracellular alkalosis and extracellular acidosis in cancer
Tomas Koltai
Seminars in Cancer Biology.2017; 43: 139. CrossRef

11,845 View
402 Download
21 Web of Science
18 Crossref

Case Report

Benign Metastasizing Leiomyoma with Multiple Lymph Node Metastasis: A Case Report: Gun Yoon, Tae-Joong Kim, Chang-Ohk Sung, Chel Hun Choi, Jeong-Won Lee, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim; Cancer Res Treat. 2011;43(2):131-133. Published online June 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.2.131

Abstract PDF PubReader ePub

This is a case report about benign metastasizing leiomyoma with multiple lymph node metastasis. A 34-year-old woman received an abdominal myomectomy for a suspicious leiomyoma. On the pathology report, atypical leiomyoma was suspected. Due to the suspicion of multiple lymph node metastasis on pelvis computed tomography (CT) 1 year after the operation, she was transferred to the Samsung Medical Center on October, 2009 for further work up. According to original slide review, it was determined to be a benign leiomyoma with a mitotic count <5/10 high-power fields, little cytological atypia and no tumor cell necrosis. Additional immunostaining was done. Multiple lymph node metastasis and a small lung nodule were identified on positron emission tomogarphy-CT and chest CT. Extensive debulking surgery and diagnostic video-assisted thoracoscopic surgery (VATS) wedge resection were subsequently done. Metastatic lesions were reported to have a histology similar to that of the original mass. VATS right upper lobectomy with mediastinal lymph node dissection was performed because of the pathology result of VATS (adenocarcinoma). She started taking an aromatase inhibitor (Letrozole(R)) and there was no evidence of recurrence of disease on an imaging study and no post-operative complications until recently.

Citations

Citations to this article as recorded by

Molecular genetic analysis of pulmonary benign metastasizing leiomyoma and intravenous leiomyomatosis: a comparative study using whole exome sequencing
Jin Li, Jiafei Zeng, Shuai Luo, Jinjing Wang
Discover Oncology.2025;[Epub] CrossRef
Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature
Aleksandra Piórek, Adam Płużański, Piotr Wiśniewski, Sylwia Tabor, Kinga Winiarczyk, Magdalena Knetki-Wróblewska, Dariusz M. Kowalski, Maciej Krzakowski
Diseases.2024; 12(8): 181. CrossRef
Leiomiomatosis pulmonar benigna metastatizante: una causa rara de nódulos pulmonares. Reporte de caso
María Angélica Moreno Carrillo, María Carolina Torres, Alfredo Saavedra, Rafael Parra Medina
Revista Colombiana de Neumología.2024; 36(1): 48. CrossRef
Benign metastasizing uterine leiomyoma with lymphatic and pulmonary metastases: a case report and literature review
Tong Tong, Qiong Fan, Yudong Wang, Yuhong Li
BMC Women's Health.2023;[Epub] CrossRef
Pulmonary benign metastasizing uterine leiomyoma (PBML): a case report and review of the literature
Mark R. Brincat, Sarah Lam Shang Leen, Asma Faruqi, Michail Sideris, Kelvin Kar Wing Lau, Alexandra Lawrence
Annals of Medicine & Surgery.2023; 85(7): 3686. CrossRef
Benign Metastasizing Leiomyoma of the Lung: Diagnostic Process and Treatment Based on Three Case Reports and a Review of the Literature
Małgorzata Edyta Wojtyś, Olga Kacalska-Janssen, Konrad Ptaszyński, Piotr Lisowski, Michał Kunc, Janusz Wójcik, Tomasz Grodzki
Biomedicines.2022; 10(10): 2465. CrossRef
A case report of atypical uterine leiomyoma
Yun Sook Kim, Hyun Joo Lee
Medicine: Case Reports and Study Protocols.2021; 3(11): e0168. CrossRef
Metastatic leiomyoma or synchronous lesion of the uteri corpus and vulva?
I. V. Barinova, S. N. Buyanova, N. I. Kondrikov, N. A. Shchukina, I. N. Voloshchuk, M. V. Mgeliashvili, S. A. Petrakova, A. A. Aksenova
Arkhiv patologii.2020; 82(1): 62. CrossRef
Lung metastases from benign uterine leiomyoma: does 18-FDG-PET/CT have a role to play?
Feras Abu Saadeh, Ciaran O. Riain, Ciara Mc Cormack, Noreen Gleeson
Irish Journal of Medical Science (1971 -).2019; 188(2): 619. CrossRef
Benign metastasising leiomyoma with lymph node metastases in a patient with endometrial cancer after caesarean section
Serra Akar, Serdar Ugras, Gozde Sahin, Fatih Demir, Çetin Çelik
Journal of Obstetrics and Gynaecology.2019; 39(3): 420. CrossRef
Benign metastasizing leiomyoma presenting with miliary pattern and fatal outcome: Case report with molecular analysis & review of the literature
Kenneth Ofori, Helen Fernandes, Matthew Cummings, Thomas Colby, Anjali Saqi
Respiratory Medicine Case Reports.2019; 27: 100831. CrossRef
Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study
Sanam Moradan
Journal of Menopausal Medicine.2018; 24(1): 62. CrossRef
The Heart as a Site of Metastasis of Benign Metastasizing Leiomyoma: Case Report and Review of the Literature
Mariam Meddeb, Robert D. Chow, Randolph Whipps, Reyaz Haque
Case Reports in Cardiology.2018; 2018: 1. CrossRef
BENIGN UTERUS CANCER WITH LUNG METASTASES: LEIOMYOMATOSIS, LYMPHANGIOLEIMYOMATOSIS, THORACIC ENDOMETRIOSIS (LITERATURE REVIEW, PERSONAL CLINCIAL OBSERVATIONS)
Леншин, Anatoliy Lenshin, Ильин, Andrey Il'in, Демура, Ol'ga Demura, Крайнов, Sergey Kraynov, Побережский, Aleksey Poberezhskiy
Bulletin physiology and pathology of respiration .2017; : 30. CrossRef
Benign metastasizing leiomyoma and 18-FDG-PET/CT: A case report and literature review
Yusuke Sawai, Toshiki Shimizu, Yuta Yamanaka, Maiko Niki, Shosaku Nomura
Oncology Letters.2017; 14(3): 3641. CrossRef
Mesothelial cell deposits in lymph nodes—a diagnostic pitfall
Archana Pandita, Vladimir Osipov
Annals of Diagnostic Pathology.2016; 25: 31. CrossRef
Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo
Clasina M. Venema, Giulia Apollonio, Geke A.P. Hospers, Carolina P. Schröder, Rudi A.J.O. Dierckx, Erik F.J. de Vries, Andor W.J.M. Glaudemans
Clinical Nuclear Medicine.2016; 41(11): 844. CrossRef
Single benign metastasising leiomyoma of an inguinal lymph node
Kamil G Laban, Roberto E Tobon-Morales, Janice A L Hodge, Henk W R Schreuder
BMJ Case Reports.2016; 2016: bcr2016216546. CrossRef
Leiomyomas beyond the uterus; benign metastasizing leiomyomatosis with paraaortic metastasizing endometriosis and intravenous leiomyomatosis: a case series and review of the literature
Mohamad S. Mahmoud, Kavita Desai, Farr R. Nezhat
Archives of Gynecology and Obstetrics.2015; 291(1): 223. CrossRef
Benign pulmonary metastasizing leiomyoma of the uterus: A case report
HUI MA, JIE CAO
Oncology Letters.2015; 9(3): 1347. CrossRef
Single-port laparoscopic debulking surgery of variant benign metastatic leiomyomatosis with simultaneous lymphatic spreading and intraperitoneal seeding
Yoo Hyun Chung, Suk Woo Lee, So Young Shin, Chae Chun Rhim, Soyoung Im, Sie Hyeon Yoo, Joo Hee Yoon
Obstetrics & Gynecology Science.2015; 58(4): 314. CrossRef
Benign metastasizing leiomyoma of the lung: A case report and literature review
WEI-TIAN WEI, PENG-CHENG CHEN
Oncology Letters.2015; 10(1): 307. CrossRef
Difficulty in complete transarterial embolization for pulmonary benign metastasizing leiomyoma with massive hemoptysis
Masaya Miyazaki, Akie Nakayama, Daichi Noda, Yasunobu Maehara, Yoshito Tsushima
Japanese Journal of Radiology.2014; 32(1): 53. CrossRef
Pulmonary leiomyomas in a patient with bilateral renal cell cancer mimicking pulmonary metastases
Ying-Yi Chen, Seng-Tang Wu, Hsian-Her Hsu, Ya-Cheng Chen, Shih-Chun Lee, Hung Chang, Tsai-Wang Huang
Clinical Imaging.2014; 38(3): 330. CrossRef
Incidental Benign Metastasizing Leiomyoma in a Patient with Bone Sarcoma: A Case Report
Zanndor Jacob del Real-Romo, Carlos Montero-Cantú, Oscar Villegas-Cabello, José Antonio Díaz-Elizondo, Danae Reyes-Salas, Rene Palomo-Hoil, Guillermo Peralta-Castillo, David Martínez-Sánchez, Eduardo Flores-Villalba
Case Reports in Surgery.2014; 2014: 1. CrossRef
Metastasizing Leiomyoma to Heart
Erin N. Consamus, Michael J. Reardon, Alberto G. Ayala, Mary R. Schwartz, Jae Y. Ro
Methodist DeBakey Cardiovascular Journal.2014; 10(4): 251. CrossRef
METASTASISING LEIOMYOMA- A CASE REPORT
Krishna Govindan, Sheela Kuzhiveli Mohammed Ali, Lekshmy Kausthubham Sudheendran
Journal of Evolution of Medical and Dental Sciences.2014; 7(42): 4591. CrossRef
Benign Metastatic Leiomyoma Presenting as a Hemothorax
Anna M. Ponea, Creticus P. Marak, Harmeen Goraya, Achuta K. Guddati
Case Reports in Oncological Medicine.2013; 2013: 1. CrossRef
Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review
Erin I. Lewis, Rebecca J. Chason, Alan H. DeCherney, Alicia Armstrong, John Elkas, Aradhana M. Venkatesan
Fertility and Sterility.2013; 99(7): 2017. CrossRef
Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models
Bosung Shim, Gustavo Pacheco-Rodriguez, Jiro Kato, Thomas N. Darling, Martha Vaughan, Joel Moss
European Respiratory Review.2013; 22(129): 302. CrossRef
Pulmonary benign metastasizing leiomyoma: a case report and review of the literature
Yili Fu, Hui Li, Bo Tian, Bin Hu
World Journal of Surgical Oncology.2012;[Epub] CrossRef

12,596 View
71 Download
31 Crossref

Original Article

MR Imaging in Endometrial Carcinoma as a Diagnostic Tool for the Prediction of Myometrial Invasion and Lymph Node Metastasis: Ui Nam Ryoo, Chel Hun Choi, Ji Yeong Yoon, Soo Kyung Noh, Heeseok Kang, Woo Young Kim, Boh Hyun Kim, Tae-Joong Kim, Jeong-Won Lee, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae; Cancer Res Treat. 2007;39(4):165-170. Published online December 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.4.165

Abstract PDF PubReader ePub

Purpose

The purpose of this study was to evaluate the factors that are associated with the accuracy of magnetic resonance (MR) imaging for predicting myometrial invasion and lymph node metastasis in women with endometrial carcinoma.

Materials and Methods

We retrospectively reviewed the medical records and preoperative MR imaging reports of 128 women who had pathologically proven endometrial carcinoma. We compared the MR imaging and the histopathology findings.

Results

The sensitivity, specificity and accuracy for identifing any myometrial invasion (superficial or deep) were 0.81, 0.61 and 0.74, respectively; these values for deep myometrial invasion were 0.60, 0.94 and 0.86, respectively. The sensitivity, specificity and accuracy of MR imaging for detecting lymph node metastasis were 50.0%, 96.6% and 93.0%, respectively. The patients who were older, had more deliveries and a larger tumor size more frequently had incorrect prediction of deep myometrial invasion (p=0.034, p=0.044, p=0.061, respectively). A higher tumor grade, a histology other than the endometrioid type, myometrial invasion on MR findings and a larger tumor size were associated with a more frequent false-negative prediction of lymph node metastasis (p=0.018, p=0.017, p=0.002, p=0.047, respectively). A larger tumor size was also associated with more frequent false-positive results (p=0.009).

Conclusions

There are several factors that make accurate assessment of myometrial invasion or lymph node metastasis difficult with using MRI; therefore, the patients with these factors should have their MR findings cautiously interpreted.

Citations

Citations to this article as recorded by

Magnetic resonance imaging pitfalls in determining myometrial invasion in stage I endometrial cancer: A case report and literature review
Hariyono Winarto, Muhammad Habiburrahman, Trifonia Pingkan Siregar, Kartiwa Hadi Nuryanto
Radiology Case Reports.2022; 17(8): 2680. CrossRef
Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis
Casper Reijnen, Joanna IntHout, Leon F.A.G. Massuger, Fleur Strobbe, Heidi V.N. Küsters-Vandevelde, Ingfrid S. Haldorsen, Marc P.L.M. Snijders, Johanna M.A. Pijnenborg
The Oncologist.2019; 24(9): e880. CrossRef
Feasibility of a reduced field‐of‐view diffusion‐weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer
Priya Bhosale, Jingfei Ma, Revathy Iyer, Preetha Ramalingam, Wei Wei, Pamela Soliman, Michael Frumovitz, Vikas Kundra
Journal of Magnetic Resonance Imaging.2016; 43(2): 316. CrossRef
Contrast‐enhanced MRI in preoperative assessment of myometrial and cervical invasion, and lymph node metastasis: diagnostic value and error analysis in endometrial carcinoma
Fei Teng, Yan‐Fang Zhang, Ying‐Mei Wang, Jing Yu, Xu Lang, Wen‐Yan Tian, Chang‐Xin Jiang, Feng‐Xia Xue
Acta Obstetricia et Gynecologica Scandinavica.2015; 94(3): 266. CrossRef
Magnetic Resonance Imaging in the Assessment of High-Risk Features of Endometrial Carcinoma A Meta-Analysis
Anna Luomaranta, Arto Leminen, Mikko Loukovaara
International Journal of Gynecological Cancer.2015; 25(5): 837. CrossRef
Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma
Sami K. Saarelainen, Nina Peltonen, Terho Lehtimäki, Antti Perheentupa, Maarit H. Vuento, Johanna U. Mäenpää
American Journal of Obstetrics and Gynecology.2013; 209(2): 142.e1. CrossRef
Preoperative assessment of endometrial carcinoma by three‐dimensional power Doppler angiography
S. K. Saarelainen, M. H. Vuento, P. Kirkinen, J. U. Mäenpää
Ultrasound in Obstetrics & Gynecology.2012; 39(4): 466. CrossRef
Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma
Dong Hoon Suh, Hee Seung Kim, Hyun Hoon Chung, Jae Weon Kim, Noh Hyun Park, Yong Sang Song, Soon-Beom Kang
European Journal of Obstetrics & Gynecology and Reproductive Biology.2012; 162(2): 206. CrossRef
The preoperative assessment of deep myometrial invasion by three‐dimensional ultrasound versus MRI in endometrial carcinoma
SAMI K. SAARELAINEN, LEA KÖÖBI, RITVA JÄRVENPÄÄ, MARITA LAURILA, JOHANNA U. MÄENPÄÄ
Acta Obstetricia et Gynecologica Scandinavica.2012; 91(8): 983. CrossRef

10,182 View
91 Download
9 Crossref

First
Prev
Page of 1
Next
Last

Search